News | February 26, 2008

Micro Implantable Blood Pump Improves Quality of Life, Preliminary Results Find

February 27, 2008 - CircuLite Inc. released preliminary results of a pilot first-in-man study of four patients who have been implanted with the Synergy Pocket Circulatory Assist Device, a micro implantable blood pump, the size of a AA battery, that can be implanted superficially in a “pacemaker-like” pocket.

The device is designed to provide long-term, partial circulatory support in patients with chronic heart failure.

Four patients were enrolled in the pilot study, which was initiated in June 2007 and evaluated Synergy in individuals awaiting a heart transplant. All patients reached the primary endpoint of successful heart transplantation, with one patient supported for 7 months, said CicuLite. Final data from this study will be presented at a future medical meeting.

“Patients implanted with Synergy thus far have demonstrated significant clinical improvements in hemodynamics and, importantly, quality of life,” said Bart Meyns, M.D., Ph.D., professor and chief of cardiac surgery at Gasthuisberg University Hospital (Katholieke Universiteit) in Leuven, Belgium. “This system was designed to improve the quality of life of chronic heart failure patients by giving them a less invasive option to increase blood flow from the heart, so we are encouraged to see that initial patient experiences have been consistent with this goal.”

The pilot study cohort will be included in CircuLite’s 20-patient long-term support CE Mark trial that is currently enrolling patients. The CE Mark trial is designed to support a CE Mark filing at the end of 2008, said the company.

For more information: www.CircuLite.net

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init